BUILT Biotechnologies, an emerging leader in DNA Manufacturing-as-a-Service, today announced its selection as an anchor company at the Commonwealth BioAccelerator, a strategic initiative led by CvilleBioHub to strengthen Virginia’s biotechnology ecosystem. The company’s headquarters relocation to CvilleBioHub’s state-of-the-art facilities at North Fork Research Park marks a significant step in BUILT’s rapid growth trajectory. The move will allow BUILT to expand its production capacity, establish a next-generation laboratory, and tap into Charlottesville’s skilled talent pool to accelerate innovation and scale operations in response to surging customer demand.
Through its proprietary Regenerative DNA Assembly™ process, BUILT Biotechnologies is redefining how organizations access high-quality, ready-to-use DNA. This innovative approach bridges the gap between traditional DNA synthesis and the delivery of functional, application-ready DNA molecules, providing researchers and developers with faster, more reliable, and more cost-effective DNA solutions. BUILT’s platform serves a growing nationwide customer base that includes top-10 biopharmaceutical companies, university core facilities, and emerging biotech startups. By enabling these groups to access complex and high-fidelity DNA constructs on demand, BUILT is helping accelerate cutting-edge programs in cell and gene therapy, RNA therapeutics, and synthetic biology.
BUILT’s service model centers on its flagship product, BUILT DNA™, which delivers sequence-perfect DNA constructs—including long or “unbuildable” molecules—available in both linear and plasmid formats. By eliminating the need for in-house DNA assembly, BUILT helps life science innovators save time, reduce costs, and streamline R&D workflows, empowering them to move from concept to experimentation faster than ever.
George McArthur, PhD, CEO of BUILT Biotechnologies, commented on the milestone, saying:
“Our designation as an anchor company at the Commonwealth BioAccelerator validates BUILT’s rapid emergence as the partner of choice for life science organizations seeking a faster, more efficient way to access high-quality, ready-built DNA. Our new North Fork laboratory gives us the infrastructure to meet the growing market demand, while positioning us to recruit exceptional local talent and deepen our collaboration with CvilleBioHub.”
The North Fork Research Park expansion will also enable BUILT to collaborate closely with the Paul and Diane Manning Institute of Biotechnology at the University of Virginia, leveraging regional expertise to enhance research partnerships and contribute to the state’s growing biotech sector. This alignment strengthens BUILT’s ability to serve both global innovators and Virginia-based enterprises, reinforcing the company’s dual commitment to scientific advancement and local economic development.
Nikki Hastings, PhD, Executive Director of CvilleBioHub, highlighted BUILT’s strategic role in advancing the region’s biotech ecosystem:
“BUILT exemplifies the kind of scale-ready company we’re proud to champion in Central Virginia. As an anchor company of the Commonwealth BioAccelerator, BUILT brings mission-critical DNA manufacturing capacity to the ecosystem—helping therapeutic developers move from idea to impact faster and more reliably.”
The Commonwealth BioAccelerator, operated by CvilleBioHub and supported by a coalition of public and private partners, was established to empower high-potential biotech companies with the infrastructure, resources, mentorship, and community needed to scale successfully in Virginia. BUILT’s selection as an anchor company underscores its position as a cornerstone of the state’s emerging bioeconomy and a model for how platform-based biotech manufacturing can catalyze regional growth.
As demand for DNA manufacturing and assembly services continues to climb—driven by the expansion of gene editing, RNA-based therapeutics, and next-generation synthetic biology applications—BUILT Biotechnologies is poised to play a defining role in meeting that need. The company’s technology and service model directly address one of biotechnology’s most persistent bottlenecks: the ability to produce long, accurate, and complex DNA sequences rapidly and affordably.
With its new headquarters, enhanced production capabilities, and strengthened academic and industry partnerships, BUILT Biotechnologies is positioned at the forefront of a new era in DNA manufacturing, empowering scientists and developers to build with biology at unprecedented speed and scale.
